On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

DGE 3rd Diversity in Clinical Trials Invites Pharmaceutical Professionals for Enlightening Discussions

DGE invites life science professionals to attend the 3rd Diversity In Clinical Trials Conference being held on May 15-16, 2024 at the Inn at Penn Philadelphia. The conference offers an valuable forum for meaningful interactions to understand the intricacies of and benefits of pursuing diverse enrollment in clinical studies.

The event is hosted by Dynamic Global Events (“DGE”), a global leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotech, medical devices, and all healthcare industries.

New insights and successful strategies are pivotal for better clinical trial results. Pharma colleagues gather for a focused approach towards diversity, equity, and inclusion (DEI) for clinical trials. Having a complete understanding of the complexities and challenges of diverse participation in clinical trials will help organizations make the necessary changes in their planning and execution.

The event will be attended by a diverse group of industry veterans who will share their experience and views on improving diversity in organizations. The well-rounded agenda of the conference explores all issues and challenges of diverse enrolment in clinical trials.

The conference agenda includes:

  • Examining the past and present issues of DCT, the measures taken to solve these issues, and ways of improvisation for future achievements
  • Understanding the pivotal role of DCT in the life sciences industry for developing the most effective treatments for patients
  • A great learning session offering tips to avoid repeating mistakes and discussing new avenues for improvement and development
  • An important discussion on Digital Accessibility for Clinical Trial Diversity

After the registration, the event starts with the chairperson’s opening remarks. This is followed by speaker sessions, interaction, group discussions and networking among the attendees of the conference.

To learn more please visit https://nnw.fm/vSyv3.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217